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ABSTRACT: Inhibitors of bacterial DD-peptidases represent potential antibiotics.
In the search for alternatives to β-lactams, we have investigated a series of compounds
designed to generate transition state analogue structures upon reaction with DD-
peptidases. The compounds contain a combination of a peptidoglycan-mimetic
speciﬁcity handle and a warhead capable of delivering a tetrahedral anion to the
enzyme active site. The latter includes a boronic acid, two alcohols, an aldehyde, and
a triﬂuoroketone. The compounds were tested against two low-molecular mass class
C DD-peptidases. As expected from previous observations, the boronic acid was
a potent inhibitor, but rather unexpectedly from precedent, the triﬂuoroketone
[D-α-aminopimelyl(1,1,1-triﬂuoro-3-amino)butan-2-one] was also very eﬀective.
Taking into account competing hydration, we found the triﬂuoroketone was the
strongest inhibitor of the Actinomadura R39 DD-peptidase, with a subnanomolar (free
ketone) inhibition constant. A crystal structure of the complex between the triﬂuoroketone and the R39 enzyme showed that a
tetrahedral adduct had indeed formed with the active site serine nucleophile. The triﬂuoroketone moiety, therefore, should be
considered along with boronic acids and phosphonates as a warhead that can be incorporated into new and eﬀective DD-peptidase
inhibitors and therefore, perhaps, antibiotics.
The bacterial DD-peptidases are of considerable impor-tance in medical practice because they are the targets of
β-lactam antibiotics.1 These enzymes catalyze the ﬁnal
transpeptidation reaction in the biosynthesis of bacterial cell
walls and are essential to bacterial survival. The β-lactams,
acting as mechanism-based, transition state analogue inhibitors,2−4
are precisely structured to inactivate DD-peptidases in a manner
that these enzymes have been unable to escape through
evolution of a hydrolytic pathway. Bacteria have, however, been
able to achieve resistance to β-lactams in a number of ways
unrelated to DD-peptidase active site structure and, in particular,
through evolution of β-lactamases from DD-peptidases.2,4 The
β-lactamases, unlike DD-peptidases, are able to catalyze rapid
β-lactam hydrolysis and thus destruction of their antibiotic
activity.5
The rapid evolution of β-lactamases in response to new
β-lactam antibiotics and also to β-lactam-based β-lactamase
inhibitors6−8 emphasizes the need for and stimulates the search
for DD-peptidase inhibitors that are not β-lactam-based.9−15
One obvious approach is through transition state analogues,
because such molecules should, in principle, inhibit any
enzyme.16−18 Because the reactions catalyzed by DD-peptidases
in vivo are acyl transfer reactions with a covalent acyl(serine)−
enzyme intermediate (Scheme 1), substrate-based tetrahedral
anions covalently bound to the active site serine should be good
analogues of the transition states of both acylation and deacyla-
tion steps. In principle, therefore, molecule 1, in which
“peptidoglycan” is a speciﬁc peptidoglycan or peptidoglycan-
mimetic fragment and X is a reactive moiety that generates a
tetrahedral anion upon reaction with the active site serine,
would be the inhibitor of choice.
Approaches to 1 require the optimization of both pep-
tidoglycan and X. One might expect that the former goal would
be informed by studies of the substrate speciﬁcity of these en-
zymes, where a minimal, consensual, and thus broad spectrum
peptidoglycan fragment would emerge. This goal has, however,
not yet been achieved. It is true, of course, that peptidoglycan
structure varies in detail between bacterial species, but even
given this point, no consensual structure or class of privileged
structures has emerged from consideration of DD-peptidase
substrate speciﬁcity.19,20
DD-Peptidases have been classiﬁed structurally into two
groups, the low-molecular mass (LMM) and high-molecular
mass (HMM) enzymes.21 The latter group is essential for
bacterial growth and contains the killing targets of β-lactams.
Members of the former group are also inhibited by β-lactams
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but are not essential for bacterial survival, in the short term at
least. Both groups of enzymes are believed to catalyze acyl
transfer reactions of peptidoglycan, viz., transpeptidase (HMM)
and carboxypeptidase and endopeptidase (LMM) reactions.
Certain members of the LMM group, subclasses B and C, have
been shown to have strong speciﬁcity for a free amine
N-terminus in peptidoglycan substrates,19,22−27 but no strong
speciﬁcity for any particular element of peptidoglycan has
been demonstrated for the HMM enzymes.13,19,24,28,29 The
design of transition state analogue inhibitors for the latter
enzymes is thus diﬃcult.
With respect to element X of 1, some advances have been
made. In particular, boronic acids (Scheme 2) have been shown
to be eﬀective. Peptidoglycan-mimetic boronates have been
found to be potent inhibitors of LMMC enzymes.13,20
The crystal structure of a complex of one such inhibitor, 2,
with the LMMC Actinomadura R39 DD-peptidase demon-
strated the reason for its speciﬁcity.13 β-Lactam-mimetic
boronic acids (bearing the amido side chains of classical
β-lactam antibiotics rather than peptidoglycan) have also
recently been found to be quite eﬀective, although studies
of them are limited.11,12,31
Beyond boronates, other sources of X, employed with a
variety of serine hydrolases, have been alcohols, phosphonates,
aldehydes, and triﬂuoroketones, yielding, in principle, tetrahe-
dral anions 3−6, respectively.32 Some assessment of the poten-
tial of these warheads with DD-peptidases has been made pre-
viously,14,33 although no indications of great potency have been
observed. To date, the combination of motifs 3−6 with a spe-
ciﬁc peptidoglycan fragment (as in 1) has not been investigated.
In this paper, we present the synthesis and assessment of
the inhibitory activity of 7−12 versus representative LMMC
DD-peptidases. We have discovered that triﬂuoroketone 12
is a potent inhibitor of the Actinomadura R39 enzyme
and present a crystal structure of its complex with this enzyme.
■ MATERIALS AND METHODS
Commercially available reagents and solvents were purchased
from Aldrich and Acros Organics and used without puriﬁcation,
unless otherwise noted. D-Glutamic acid and N-(Z)-D-alanine
were purchased from ChemImpex. Triﬂuoroacetaldehyde
hydrate was purchased as a 75% solution in water from
AlfaAesar. Compounds 24 (AlfaAesar), 25, and 27 were
commercial products. Triﬂuoroketone 26 was synthesized
in this laboratory by A. Shilabin. (Phenylacetyl)glycyl-D-
thiolactate (14) and boronic acid 2 were synthesized as
previously described.30 The Actinomadura R39 DD-peptidase
and Bacillus subtilis PBP4a were expressed and puriﬁed as
described previously.34,35
Varian Mercury 300 and 400 MHz NMR spectrometers
were used to collect 1H, 31P, and 19F NMR spectra. Absorption
spectra and spectrophotometric reaction rates were measured
with Hewlett-Packard 8452A and 8453 spectrophotometers.
High-resolution mass spectra (HRMS) were obtained from the
Mass Spectrometry Laboratory (School of Chemical Sciences,
University of Illinois, Urbana, IL). Routine ESI mass spectra
were recorded with a Thermo LCQ Advantage instrument.
High-performance liquid chromatography puriﬁcation was
achieved by a Varian ProStar unit equipped with a Varian
ProStar model 340 UV−vis detector and a Nucleosil C-18
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chromatography was performed on Silicycle 60 Å, 32−63 μm
silica gel.
Syntheses. D-6-(N,N′-Dibenzylamino)-6-(benzyoxylcar-
bonyl)-trans-hex-2-enoic Acid 19 (Scheme 3). N,N-Dibenzyl-
D-glutamic Acid Dibenzyl Ester 15. This compound was syn-
thesized following a previously reported general method.36 It
was puriﬁed by chromatography on silica gel (7:1 hexane:ethyl
acetate) producing 15 as a colorless oil in 60% yield: 1H NMR
(CDCl3, 300 MHz) δ 2.1 (q, J = 7.5 Hz, 2H), 2.43, 2.56
(d quint, J = 9, 9 Hz, 2H), 3.47 (t, J = 7.5 Hz, 1H), 3.55, 3.93
(AB q, J = 13.5 Hz, 4H), 5.26 (AB q, J = 3 Hz, 2H), 5.20, 5.32
(AB q, J = 12 Hz, 2H), 7.25−7.46 (m, 20H).
D-4-(N,N-Dibenzylamino)-4-(benzyloxycarbonyl)butanal
16. To a stirred solution of 15 (3 g, 6 mmol, 1 equiv) in 30 mL
of anhydrous diethyl ether under a nitrogen atmosphere was
added DIBAL (1 M in hexane, 6.5 mL, 1.1 equiv) slowly at
−78 °C. The reaction mixture was stirred for 15 min, and then
water (0.3 mL) was added. The reaction mixture was allowed
to warm to room temperature and stirred for an additional
30 min; it was then dried over magnesium sulfate and ﬁltered,
and the volatiles were evaporated, leaving a colorless gum, 16
(2.2 g), which was employed in the next step without puri-
ﬁcation: 1H NMR (CDCl3, 300 MHz) δ 1.21 (t, J = 7.8 Hz,
2H), 2.3−2.5 (m, 2H), 3.35 (t, J = 7.2 Hz, 1H), 3.52, 3.86
(AB q, J = 13.5 Hz, 4H), 5.20, 5.26 (AB q, J = 10.8 Hz, 2H),
7.2−7.5 (m, 15H), 9.58 (s, 1H).
D-6-(N,N-Dibenzylamino)-6-(benzyloxycarbonyl)-trans-
hex-2-enoic Acid tert-Butyl Ester 18. To a stirred solution
of 16 (2.0 g, 5 mmol, 1 equiv) in dry THF (20 mL) was
added (tert-butoxycarbonylmethylene)triphenylphosphorane
17 (Aldrich) (2.6 g, 6.8 mmol, 1.2 equiv) at room temperature.
The reaction mixture was stirred for 1.5 h, after which solvent
was removed by evaporation. The crude product was puriﬁed
by chromatography on silica gel (3:1 hexane:ethyl acetate),
Scheme 3a
aReagents and conditions: (a) BnBr, NaOH, K2CO3, H2O, reﬂux, 60%; (b) DIBAL-H, Et2O, −78 °C, 65%; (c) 17, THF, 25 °C, 1.5 h; (d) TFA,
CH2Cl2, 0 °C, 1 h, 90%.
Scheme 4a
aReagents and conditions: (a) nitroethane, K2CO3, 50−60 °C, 3 h, 62%; (b) H2, 40 psi, 10% (w/w) PtO2, MeOH/CHCl3 (16:1), 12 h, 86%; (c) 19,
HBTU, Et3N, 25 °C, 24 h, 80%; (d) Dess−Martin periodinane, TFA, CH2Cl2, 25 °C, 3 h, 90%; (e) H2, 40 psi, 10% (w/w) Pd/C, MeOH, 12 h, 35%.
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yielding product 18 as a colorless oil (1.5 g, 60% yield): 1H
NMR (CDCl3, 300 MHz) δ 1.47 (s, 9H), 1.86 (m, 2H), 2.07
(m, 1H), 2.32 (m, 1H), 3.34 (t, J = 7.5 Hz, 1H), 3.53, 3.87 (AB
q, J = 13.5 Hz, 4H), 5.19, 5.25 (AB q, J = 10.8 Hz, 2H), 5.59
(d, J = 16 Hz, 1H), 6.70 (quint, J = 7.2 Hz, 1H), 7.2−7.4
(m, 15H).
D-6-(N,N-Dibenzylamino)-6-(benzyloxycarbonyl)-trans-
hex-2-enoic Acid 19. Ester 18 (0.5 g, 1 mmol) was dissolved in
dichloromethane (5 mL). To this solution, stirred in an ice
bath, was slowly added triﬂuoroacetic acid (6 mL). The
reaction mixture was stirred for 1 h at room temperature, after
which the solvent was evaporated. After the residue was dried
under vacuum, product 19 was obtained as a gum (0.4 g, 90%
yield): 1H NMR (CDCl3, 300 MHz) δ 1.86 (m, 2H), 2.07 (m,
1H), 2.32 (m, 1H), 3.34 (t, J = 7.5 Hz, 1H), 3.53, 3.87
(AB q, J = 13.5 Hz, 4H), 5.19, 5.25 (AB q, J = 10.8 Hz, 2H),
5.59 (d, J = 16 Hz, 1H), 6.7 (quint, J = 7.2 Hz, 1H), 7.2−7.4
(m, 15H); ES(+)MS m/z 444.4 (M + 1).
D-α-Aminopimelyl(1,1,1-triﬂuoro-3-amino)butan-2-one
(Scheme 4). 3-Nitro-1,1,1-triﬂuoro-2-butanol 20. This com-
pound was prepared following the procedure reported by
McBee et al.37
Product 20 was obtained as a yellow oil in 62% yield: 1H
NMR (300 MHz, CDCl3) δ 1.72 (d, 3H, J = 6 Hz), 3.2−3.6
(br s, 1H), 4.76−4.92 (m, 2H).
3-Amino-1,1,1-triﬂuoro-2-butanol Hydrochloride 21. This
compound was prepared as a mixture of diastereoisomers, fol-
lowing the procedure reported by Shao et al.38 The colorless
solid hydrochloride salt was obtained in 86% yield: 1H NMR
(300 MHz, d6-DMSO) δ 1.20 (d, J = 4.8 Hz, 3H), 1.27 (d, 3H,
J = 4.8 Hz), 3.40 (m, 1H), 3.53 (m, 1H), 4.14 (m, 1H), 4.38
(m, 1H), 8.06 (br s, 3H), 8.22 (br s, 3H).
D-1-[6-(N,N-Dibenzylamino)-6-(benzyloxycarbonyl)]-trans-
hex-2-enoyl-3-amino-1,1,1-triﬂuoro-2-butanol 22. To a mix-
ture of D-1-[6-(N,N-dibenzylamino)-6-(benzyloxycarbonyl)]-
trans-hex-2-enoic acid 19 (488 mg, 1.1 mmol, 1 equiv) and
3-amino-1,1,1-triﬂuoro-2-butanol hydrochloride 21, dissolved
in 10 mL of DMF, was added triethylamine (767 μL, 2.75
mmol, 2.5 equiv) followed by HBTU (1046 mg, 2.75 mmol,
2.5 equiv) at 0−5 °C. The reaction mixture was stirred at room
temperature for 24 h. The solvent was removed in vacuo and
the residue dissolved in ethyl acetate. The organic solution was
washed with 0.1 M hydrochloric acid, a saturated aqueous solu-
tion of sodium bicarbonate, and brine and dried over anhydrous
sodium sulfate. The solvent was removed in vacuo, and the
residue was puriﬁed by silica gel column chromatography (ethyl
acetate/hexane) to give product 22 in 80% yield as a colorless
oil: 1H NMR (400 MHz, CDCl3) δ 1.32 (d, 3H, J = 7.5 Hz),
1.76 (m, 2H), 2.06−2.16 (m, 1H), 2.25−2.36 (m, 1H), 3.32
(dd, J = 6 Hz, 1H), 3.46, 3.85 (AB q, J = 16 Hz, 4H), 4.07 (m, 1H),
4.28 (m, 1H), 4.83 (d, J = 7.5 Hz, 1H), 4.91 (d, J = 7.5 Hz, 1H),
5.21 (AB q, J = 16, 24 Hz, 2H), 5.40 (d, J = 5 Hz, 1H), 7.67
(m, 1H), 7.2−7.4 (m, 15 H).
D-1-[6-(N,N-Dibenzylamino)-6-(benzyloxycarbonyl)]-trans-
hex-2-enoyl-3-amino-1,1,1-triﬂuorobutan-2-one 23. To a
stirred solution of 22 (380 mg, 0.67 mmol, 1 equiv) in
dichloromethane (25 mL) at room temperature was added
Dess−Martin periodinane (850 mg, 2 mmol, 3 equiv), followed
by triﬂuoroacetic acid (150 μL, 2 mmol, 3 equiv) at room
temperature. The reaction mixture was stirred for 3 h, after
which it was quenched with a sodium bicarbonate solution and
extracted with ethyl acetate. After the solution had been dried
and the solvent evaporated, the crude product was puriﬁed on a
silica gel column (1:1 ethyl acetate/hexane), and product 23
was isolated in 90% yield as a colorless oil: 1H NMR (400
MHz, CDCl3) δ 1.39 (d, J = 8 Hz, 3H), 1.46 (d, J = 8 Hz, 3H),
1.75−1.96 (m, 2H), 2.06−2.18 (m, 1H), 2.24−2.36 (m, 1H),
3.31 (m, 1H), 3.49, 3.86 (AB q, J = 16 Hz, 4H), 4.11 (m, 1H),
4.88−5.06 (dd, J = 8 Hz, 1H), 5.2 (AB q, J = 16, 24 Hz, 2H),
5.70 (d, J = 6 Hz, 1H), 7.69 (m, 1H), 7.23 (s, 10H), 7.4
(s, 5H).
D-α-Aminopimelyl(1,1,1-triﬂuoro-3-amino)butan-2-one
12. The required ﬁnal product was prepared from 23 by
catalytic hydrogenation overnight at 40 psi in 10 mL of MeOH
with 10% Pd on carbon. After reaction, the solution was
ﬁltered, and the ﬁltrate was evaporated to dryness to give a
colorless solid. The crude product was dissolved in water and
washed with ethyl acetate three times. The aqueous solution
was separated and freeze-dried to give a colorless solid. This
was puriﬁed by two passages through a Sephadex G10 size-
exclusion chromatography column (water eluent). Product
12 was isolated in 35% yield as a colorless solid: 1H NMR
(400 MHz, D2O) δ 1.06 (d, J = 6.8 Hz, 3H), 1.22 (m, 2H),
1.46 (m, 2H), 1.70 (m, 2H), 2.12 (t, J = 7.5 Hz, 2H), 3.56
(t, J = 6 Hz, 1H), 4.15 (q, J = 7.2 Hz, 1H); 19F NMR (300
MHz, D2O) δ −82 (CF3); HRMS (ESI) [M + H]+ found
299.1220, calcd 299.1219.
Syntheses of 7−11 are described in detail in the Supporting
Information.
Enzyme Kinetics Studies. Inhibition of the Actinomadura
R39 DD-Peptidase by Compounds 7−12. In view of the nature
of the inhibitors and all precedent,20,24−26 the inhibition was
interpreted in all cases as purely competitive. Equilibrium
constants for inhibition of the R39 DD-peptidase by compounds
7 (0−3.0 mM), 10 (0−2.0 mM), 11 (0−1.0 mM), 8 (0−
400 μM), 9 (0−2.0 mM), and 12 (0−40 μM) were obtained
from steady state competition experiments in which 14 was
employed as a chromogenic (245 nm; Δε = 2500 cm−1 M−1)
substrate (0.5 mM). The reaction conditions were 20 mM
MOPS buﬀer, pH 7.50, 25 °C, and an enzyme concentration of
210 nM. Under these conditions, the Km value of the substrate
was 38.4 μM.25 Measurements of the initial velocity versus
concentrations of 7−11 were ﬁt to Scheme 5 and eq 1 to obtain
the Ki value. Total progress curves of inhibition of R39 DD-
peptidase by compound 12 were ﬁt to Scheme 8 (see below)
with Dynaﬁt39 to obtain the Ki value directly.
= + + +v V K s K i K s( )/[ (1 / ) ]0 m m i (1)
Inhibition of B. subtilis PBP4a by Compounds 7−12.
Equilibrium constants for inhibition of B. subtilis PBP4a by
compounds 7−12 were obtained in a manner similar to that
used for the constants for the R39 enzyme. The reaction con-
ditions were 20 mM MOPS buﬀer, pH 7.50, 25 °C, and an
enzyme concentration of 164 nM. Under these conditions, Km
was 0.44 ± 0.08 mM for 14 as a substrate. The total progress curves
for inhibition by compounds 8 (0−400 μM), 11 (0−1.0 mM),
Scheme 5
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and 12 (0−40 μM) were ﬁt to Scheme 5 with Dynaﬁt39 to
obtain Ki values.
The Ki values for 24−27 with both enzymes were obtained
from the measurement of initial rates at several concentrations
of inhibitor in each case and application of eq 1.
Kinetics of Aminolysis of 14 by 7−10, Catalyzed by the
R39 DD-Peptidase. Aminolysis of substrate 14 by amines 7−12,
catalyzed by the R39 DD-peptidase, involves amine attack on the
acyl−enzyme E−S intermediate (Scheme 6). The initial rates of
reaction of 14, catalyzed by this enzyme, as a function of
concentrations of 7−10 were ﬁt to Scheme 6 with Dynaﬁt.39
These experiments were conducted in 20 mM MOPS buﬀer at
pH 7.50 and 25 °C with an enzyme concentration of 210 nM.
Crystallization, Data Collection, and Structure Deter-
mination. Crystals of the enzyme were obtained by the hang-
ing drop vapor diﬀusion method by mixing 4 μL of a 25 mg/mL
protein solution [also containing 5 mM MgCl2 and 20 mM
Tris (pH 8.0)], 2 μL of a well solution [2.0 M ammonium
sulfate and 0.1 M MES (pH 6)], and 0.5 μL of 0.1 M CoCl2.
Crystals were soaked in 6 μL of a solution containing 3.0 M
ammonium sulfate, 0.1 M MES (pH 6.0), and 0.5 μL of
0.5 M 12.
Data for the R39−12 crystals were measured on beamline
PROXIMA at SOLEIL (Paris, France) and processed using
XDS. Molecular replacement processed with the native struc-
ture produced an interpretable density map, which clearly shows
12 in the four monomers of the asymmetric unit. Reﬁnement
was conducted with Refmac,40 Coot,41 and TLS42 with ﬁnal
R and Rfree values of 19.3 and 23.7%, respectively. Data col-
lection and reﬁnement statistics are summarized in Table 1.
■ RESULTS AND DISCUSSION
Synthesis of the new compounds 7−12 was achieved in a
straightforward fashion (Schemes 3 and 4 and Schemes S1−S5
of the Supporting Information) via the versatile intermediate
19. They were all characterized by NMR and MS methods. All,
along with the carboxylate 13 and simple functional group
analogues 24−27, were treated as rapid equilibrium competitive
inhibitors of two LMMC DD-peptidases, the Actinomadura R39
DD-peptidase and B. subtilis PBP4a. No indications of slow
binding were observed in any case. Values of the inhibition
constant, Ki, obtained for 7−12, along with those for 2 and 13,
previously determined,30 are as reported in Table 2.
Alcohols 7 and 8 had very little inhibitory activity against
either enzyme. Even the triﬂuoromethyl substituent of 8, which
should reduce the alcohol pKa into a range where its anion
would be accessible to the active site oxyanion hole, produced
only a weak inhibitor of PBP4a. Conﬁguration 3 of alcohols at
the active site is therefore unfavorable. It should be noted in
passing that alcohol 8 was obtained as a mixture of four
diastereoisomers in roughly equal amounts (see the 19F NMR
data in the Supporting Information), only one of which would
be expected to be an inhibitor (2R,3S). Serine hydrolases, in
Scheme 6
Table 1. Data Collection and Reﬁnement Statistics
Data Collectiona
space group P21
cell dimensions a = 103.6 Å, b = 91.7 Å, c = 106.9 Å,
β = 94.30°
resolution range (Å) 48.9−2.6 (2.74−2.6)




completeness (%) 100 (100)
⟨I⟩/⟨σI⟩ 13.5 (3.3)
Reﬁnement
resolution range (Å) 47.9−2.6
no. of non-hydrogen protein atoms 13891
no. of water molecules 322
Rcryst (%) 19.3
Rfree (%) 23.7
root-mean-square deviation from ideal
stereochemistry
bond lengths (Å) 0.007
bond angles (deg) 1.00
mean B factor (all atoms) (Å2) 60.7
mean B factor (ligands) (Å2) 45.0
Ramachandran plotc
favored regions (%) 96.9
allowed regions (%) 3.1
outlier regions (%) 0.0
PDB entry 3zcz
aStatistics for the highest-resolution shell are given in parentheses.
bRmerge = ∑|Ii − Im |/∑Ii, where Ii is the intensity of the measured
reﬂection and Im is the mean intensity of all symmetry-related
reﬂections. Values in parentheses are for the outer resolution shell.
cUsing rampage.63
Table 2. Inhibition of DD-Peptidases by Speciﬁc Inhibitors
R39 PBP4a
inhibitor Ki (μM) k4 (s
−1 M−1) Ki (μM)
2 0.032a (0.5)b NOd 0.007 ± 0.001
0.057 ± 0.001c
7 6700 ± 100c (3000) (6.1 ± 0.4) × 103 >1000 (1000)
8 1250 ± 50c,e (500) (2.1 ± 0.1) × 104 (110 ± 25)e (300)
9 NIc,f (2000) (2.9 ± 0.1) × 102 NDg
10 NIc,f (2000) ≤1.0 × 102 NDg
11h (76 ± 13) (1000) NOd (500 ± 150) (1000)
12h (0.37 ± 0.04)i (2.2 ± 0.1) × 103 (13.5 ± 0.3)i (300)
(0.17 ± 0.02)c,i
13 480j 3.0 × 103 j NDg
aFrom ref 30. bHighest inhibitor concentration (micromolar)
employed in parentheses. cFluorescence experiment (see the text).
dNo rate acceleration observed at the highest concentration employed.
eObserved value divided by 4, because it is assumed that only one of
the four diastereomers present has signiﬁcant activity (see the text).
fNo inhibition observed at the highest concentration employed. gNot
determined. hKi values not corrected for hydration; see the text for
corrected values. iObserved value divided by 2, because it is assumed
that only one of the two diastereomers present has signiﬁcant activity
(see the text). jFrom ref 25.
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general, are not eﬃciently inhibited by alcohols, even when
speciﬁc (e.g., refs 43 and 44). Phosphonates 9 and 10 were also
ineﬀective against the DD-peptidases. Presumably, conﬁguration
28 is not favorable either. A series of arylamidophosphonic
acids was also found to lack signiﬁcant inhibitory activity
against the R39 DD-peptidase.12 Speciﬁc aryl phosphonate esters
are known to be time-dependent covalent inhibitors of
β-lactamases45 and (weakly) of a LMMB DD-peptidase.46 No
time-dependent inhibition of the present LMMC DD-peptidases
by 9, however, was observed.
Carboxylate 13 is also a weak inhibitor of the R39 enzyme
(Table 2). The trigonal carboxylate apparently does not sit well
in the oxyanion hole. This is, in fact, seen in the crystal struc-
ture of a complex of the carba analogue of 13 with the R39
DD-peptidase,26 where the carboxylate is oriented away from the
oxyanion hole. It is certainly reasonable that 13, the product of
a DD-carboxypeptidase or endopeptidase reaction, would be a
poor inhibitor.
Both of the speciﬁc carbonyl compounds 11 and 12 are
inhibitors of both LMMC enzymes. Triﬂuoroketone 12 is
particularly eﬀective (it is assumed that only one of the two
diasteromers of 12, present in approximately equal amounts,
has signiﬁcant activity; this isomer, seen in the crystal structure
described below, has D-stereochemistry at the ketone terminus).
It is likely (also see below) that these carbonyl compounds
form tetrahedral adducts 4 and 5, respectively, at the active site.
The greater eﬀectiveness of the triﬂuoroketone is likely to be
due in part to the higher alcohol acidity of the adduct,47
allowing thermodynamically more favorable formation of 6
than 5 at pH 7.5 (pKa values of triﬂuoroethanol and ethanol are
12.4 and 16,48 respectively, favoring anion formation by the
former by a factor of 103.6). This factor is essentially suﬃcient
to rationalize the higher inhibitory potency of 12 compared to
that of 11.
If it is assumed that the reacting species of 11 and 12 are the
free carbonyls,47 then the observed or apparent Ki values of
Table 2 should be corrected for the competing hydration in
aqueous solution (Scheme 7) via eq 2
= = +K K K K[IOH ]/[I] /(1 )H 2 i iobs H (2)
where Ki
obs is the observed value. From 1H NMR spectra (not
shown), KH for 11 is 30, and therefore, from eq 2, the “real” Ki
values for the carbonyl form of 11 are 2.5 and 16.1 μM for
the R39 DD-peptidase and PBP4a, respectively. The eﬀect of
hydration is even more dramatic with 12. Although estimates of
KH for triﬂuoroacetone in the literature are curiously wide-
ranging,47,49,50 the lower limit estimate is 35.49 If the additional
eﬀect of the amido substituent is included as a factor of 30
(estimated from the KH values of acetaldehyde
49 and 11), then
a lower limit estimate of KH for 12 would be 1000. Certainly,
we are unaware of any report in the literature of NMR ob-
servation of the carbonyl form of a α-triﬂuoro-α′-amidoketone
in aqueous solution (e.g., refs 51 and 52). Thus, Ki values for
12, corrected for hydration, can be estimated to be 0.37 and
13.5 nM for the R39 DD-peptidase and PBP4a, respectively.
These estimates represent upper limits and may be an order
of magnitude larger than the real values. These carbonyl
compounds are certainly powerful inhibitors of the LMMC DD-
peptidases and, upon reaction with the enzymes, may well
generate structures resembling tetrahedral high-energy inter-
mediates or transition states (see below).
The lack of speciﬁcity of the triﬂuoromethyl moiety itself and
the importance of the speciﬁc N-terminus are conﬁrmed by the
data listed in Table 3, where the eﬀectiveness of generic
inhibitors 24−27, bearing the “warheads” of 2, 7, 11, and 12,
respectively, is displayed. Only 26 shows weak inhibition of the
R39 DD-peptidase as do 24 and 26 of PBP4a.
It was striking that the weaker “inhibitors” of the R39 DD-
peptidase, 7−9, actually produced an increase in the initial rate
of substrate turnover, as shown for 7 in Figure 1, for example.
The likely explanation for this, with established precedent,25
is that, because of their free D-amino acid termini, these com-
pounds may also act as acyl acceptors and, in cases where
enzyme deacylation is rate-determining, as is presumably true
for thiolester 14, accelerate the observed reaction. Data like
Scheme 7
Table 3. Inhibition of DD-Peptidases by Generic Inhibitors
Ki (mM)
inhibitor R39 PBP4a
24 NIa (3.0)b (0.23 ± 0.03) (3.0)
25 NIa (2.5) NDc
26 (0.27 ± 0.06) (2.0) 5.0 ± 1.6 (3.0)
27 NIa (2.5) NDc
aNo inhibition observed. bHighest inhibitor concentration (millimolar)
employed in parentheses. cNot determined.
Figure 1. Eﬀect of alcohol 7 on initial rates of turnover of thiolester
substrate 14 (0.5 mM) catalyzed by the R39 DD-peptidase. The points
are experimental, and the line represents the ﬁt of the data to Scheme
6 (see the text).
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those shown in Figure 2 were ﬁt to Scheme 6 to obtain values
for k4 (Table 2). Obviously, the k4 values for 7 and 8 are much
higher than for the anionic 9 and 10 and are comparable to that
(1.4 × 104 s−1 M−1) of the best acceptor yet discovered for this
enzyme, the good substrate 29.25 It is, however, striking that
anionic terminal carboxylate 13 is a much better acceptor than
the equally anionic phosphonates 9 and 10. The ability of
enzymes to bind carboxylates and phosph(on)ates diﬀerently
has been noticed previously,53 although the functional
signiﬁcance of the distinction here is not evident.
The acyl acceptor ability of these inhibitors probably also led
to the initially unexpected observation of an apparent decrease
in the eﬀectiveness of 12 as an inhibitor of the R39 DD-
peptidase as a function of time in experiments with substrate 14
(Figure 2). This phenomenon can be interpreted in terms of
Scheme 8, which was ﬁt to data like those shown in Figure 1
(ﬁt shown). The product, Q, of the reaction of 12 with substrate
14, which presumably is 30, must be a weak inhibitor of the
R39 enzyme. Acylation of 12 by 14 would lead to a gradual
depletion of the inhibitor in solution and thus to a decreasing
level of inhibition with time (Figure 1). The Ki value for 12
reported in Table 2 derives from the ﬁts of these data. This
phenomenon was not observed in the experiments with 12 and
PBP4a or with 11 and both enzymes probably because of the
higher concentrations of inhibitors required for the experi-
ments, leading to smaller fractional depletions of the inhibitors
in these cases.
Because of the complication created by the ability of 7 and 8
to act as strong acyl group acceptors, their activity as inhibitors,
although weaker than that of 2 and 12, could not be readily
determined from experiments in which turnover of the sub-
strate was monitored. Therefore, the binding strengths of 7 and
8 were determined from the inhibition of their irreversible
inactivation of the R39 enzyme with cefotaxime, monitored
ﬂuorimetrically.54 These measurements showed that 7 and 8
did in fact bind very weakly [at millimolar concentrations
(Table 2)]. The ﬂuorescence inhibition method was checked
with 2 and 12, with acceptable results (Table 2).
It is also striking that 11 and 12 are more eﬀective inhibitors
of the R39 enzyme than of PBP4a. This may relate to the same
order of reactivity of speciﬁc substrates with these enzymes.20
On the other hand, the analogous boronic acid 2 is a stronger
inhibitor of PBP4a than of the R39 enzyme. The latter dif-
ference, however, may relate to the interesting observation that
the binding of 2 to PBP4a is a slow (minutes; two-step?)
process,20 whereas its binding to the R39 enzyme is fast (with
respect to manual mixing times). No time dependence of
the inhibition of either of these enzymes by 11 and 12 was
observed.
Crystal Structure of the Complex of the R39 DD-
Peptidase with 12. An X-ray diﬀraction study of the title
complex was performed. Initial electron density maps resulting
from the molecular replacement were excellent for the four
protein monomers present in the asymmetric unit, allowing
a precise localization of 12 in the active site of each monomer
(Figure 3). The inhibitor 12 is covalently bonded to the active
serine Ser49; the carbonyl carbon is now tetrahedral, and the
ketone oxygen occupies the oxyanion hole, deﬁned by the
backbone NH groups of Ser49 and Thr413. The D-methyl
group is directed into a hydrophobic pocket comprised of
residues Gly148, Leu349, and Met414. As previously observed
in the structures of the R39 enzyme with boronic acid 2,30 a
cephalosporin or a peptide,26 each bearing an aminopimelic
side chain, the aminopimelyl side chain runs along a hydro-
phobic groove and is ﬁxed by a series of hydrogen bonds
between the amido group and Asn300 Nδ2 and Thr413 O
atoms, and between the terminal D-α-amino acid moiety and
the Arg351 guanidinium, the Asp142 carboxylate, and the
Ser415 hydroxyl.
The most novel elements of the structure are the position of
the triﬂuoromethyl group and its interaction with the enzyme
active site. Branching from the tetrahedral carbon bonded to
Ser49 Oγ, the CF3 group occupies the likely position of a
leaving group in the tetrahedral intermediate of a peptidase
substrate (and thus of one of the boronate hydroxyl groups
in the analogous complex with 230). An overlap of the active
site elements of the boronate 2 complex and that of the
triﬂuoroketone 12, both bearing a free D-α-aminopimelyl
Scheme 8
Figure 2. Progress curves showing turnover of substrate 14 (0.5 mM)
by the R39 DD-peptidase (0.21 μM) in the absence (−−−) and
presence () of 12 (20 μM). The empty circles are experimental, and
the lines represent ﬁts of the data to Scheme 8 (see the text).
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N-terminus, for which this enzyme is speciﬁc,20,24 is shown in
Figure 4. The inhibitors are essentially identically placed in the
active site, as would be expected for transition state analogues
with such similar structure, with the CF3 group of 12 over-
lapping directly with the “leaving group” boronate hydroxyl.
With respect to the position of the CF3 group, one O−C−C−F
dihedral angle is 57°, indicating an essentially precise staggering
of the ﬂuorine atoms with respect to the oxyanion O−. This
conformation would be expected, of course, on steric and elec-
trostatic grounds and has been observed in serine protease−
triﬂuoroketone complexes (for example, in ref 55). One
ﬂuorine atom is directed out of the active site into the solvent
where it might well interact with water molecules in the manner
observed in a variety of crystal structures.55−58 Such interac-
tions are probably more dipolar in nature than those involving
classical hydrogen bonding and are probably of ∼1 kcal/mol
strength.59,60 The other two ﬂuorine atoms appear to interact in
a bifurcated fashion at a distance of 3.0 Å each with the
hydroxyl of Ser298. This kind of arrangement has been
previously observed, for example, in a triﬂuoroketone adduct
with chymotrypsin,55 where two ﬂuorines interact with a water
molecule, and in a thrombin complex, where a similar interac-
tion with a water molecule has been observed.57 It is interesting
that the Lys52 terminal nitrogen has not moved within 4.0 Å
of a ﬂuorine atom. There are many examples of close NH···F
interactions of <3.0 Å in complexes of enzymes with ﬂuorinated
Figure 3. Crystal structure of the R39 DD-peptidase in complex with the speciﬁc triﬂuoroketone 12. In this stereoview, the electron density is an
|Fo| − |Fc| diﬀerence map calculated from the ﬁnal coordinates of the model reﬁned in the absence of ligand. The resulting positive density is shown
with green hatching and is contoured at 2.5σ. The protein backbone and side chains are colored orange, and the triﬂuoroketone is colored
gray. Heteroatoms are colored red (oxygen), blue (nitrogen), orange (sulfur), and yellow (ﬂuorine). This ﬁgure was generated using PYMOL
(http://www.pymol.sourceforge.net).
Figure 4. Superimposition of the active site residues of the complex of 12 with the R39 DD-peptidase on those of the analogous complex with
boronic acid 2.30 In this stereoview, the colors of the complex of 12 are the same as those in Figure 3. The boronate complex is colored blue except
for the heteroatoms, which are colored as in Figure 3, and boron, which is colored rose. This ﬁgure was generated using PYMOL (http://
www.pymol.sourceforge.net).
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inhibitors.55−58,61 In this case, the Lys52 amine would certainly
be protonated, in a negatively charged transition state analogue
structure as it is and where it is strongly interacting with Ser49
Oγ (2.9 Å) and Asn300 Oδ (2.8 Å) atoms.
A combination of the inhibition kinetics and the crystal
structure, both discussed above, suggests that the triﬂuor-
omethyl moiety alone does not interact speciﬁcally and tightly
with the DD-peptidase active site but acts only as part of an
electrophilic ketone that does react with the active site serine in
a cooperative fashion with the speciﬁcally binding D-α-aminopimelyl
N-terminus.26,27,30,62
■ CONCLUSIONS
Compound 12 represents the ﬁrst nanomolar triﬂuoroketone
inhibitor of a DD-peptidase. It owes its potency to the triﬂuoroketone
moiety, elevating it over the less electrophilic aldehyde 11 and
other tetrahedral species derived from 7−10, which occupy the
active site less favorably. As shown by the very limited eﬀec-
tiveness of the generic analogues 24−27, it is clear that 12 is
able to achieve its eﬀectiveness only in combination with the
strong speciﬁcity produced by the D-α-aminopimelyl terminus,
whose aﬃnity for certain LMMC DD-peptidases has been
established. This combination of the triﬂuoroketone, which
forms a tetrahedral adduct with the active site serine, and the D-
α-aminopimelyl terminus into a complete inhibitor of the R39
DD-peptidase is seen very clearly in the crystal structure of the
complex between the enzyme and 12. The triﬂuoroketone
moiety and other activated carbonyls, therefore, should be con-
sidered along with boronic acids and phosphonates as warheads
that can be incorporated into new and eﬀective DD-peptidase
inhibitors and therefore, perhaps, antibiotics.
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